Healthcare Industry News: Lipitor
News Release - October 23, 2007
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent
NEW YORK--(HSMN NewsFeed)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The calcium salt patent expires in July 2010.The patent was challenged by generic manufacturer Lek Pharmaceuticals D.D., and is one of four separate challenges to the calcium salt patent by generic companies in Spain.
Lipitor is sold in Spain under the brand names Zarator and Cardyl.
"This is a victory not only for Pfizer, but for all innovators pursuing high-risk medical discoveries and for the patients who benefit from those discoveries," said Pfizer General Counsel Allen Waxman.
Lek can seek to appeal the decision to the Supreme Court of Spain.
Source: Pfizer
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!